This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

David Sobek

Contributor

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvnia State Univeristy in 2003 and a BA in international relations from The College of William and Mary in 1997.

David Sobek
By This Author:
« Back
Page 1 of 4
Article

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

By David Sobek

Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.

08:00AM 04/16/14

Article

Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

By David Sobek

Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.

10:06AM 04/09/14

Article

Tetraphase Antibiotic Nearing Key Tolerability Test

By David Sobek

The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.

08:00AM 04/02/14

Article

Endocyte Bulls Were Right, But Bears Aren't Going Away

By David Sobek

Expect the Endocyte bear thesis to shift now that vintafolide has conditional approval in Europe and the lung cancer phase II study was positive.

10:22AM 03/25/14

Article

Onconova's MDS Study Fails and I Explain What I Got Wrong.

By David Sobek

Rigosertib performed pretty much as expected but the control arm of the study lived longer than anticipated, thereby causing the negative result.

07:30AM 02/20/14

Article

Cempra Antibiotic Candidate Clears Important Heart Safety Hurdle

By David Sobek

Cempra's solithromycin may have an important safety advantage over competing compounds.

11:29AM 02/11/14

Article

Cancer Immunotherapy Combos: The Future Despite Fuzzy Road Map

By David Sobek

A look at the myriad ways cancer immunotherapy combinations might one day benefit patients.

12:06PM 01/30/14

Article

The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron

By David Sobek

Sangamo benefits from a Biogen partnership, but what does it mean for rivals Bluebird and Acceleron?

08:00AM 01/23/14

Article

The French Cancer Immunotherapy Stock Investors Don't Know, But Really Should

By David Sobek

Innate Pharmaceuticals is developing a promising "checkpoint inhibitor" cancer drug and is partnered with Bristol-Myers Squibb.

08:00AM 01/08/14

Article

Why Investors Are Writing Off Infinity Pharma

By David Sobek

Infinity's B-cell malignancy drug is seen as too far behind competitors but can combination therapy make it more relevant?

08:00AM 12/18/13

« Back
Page 1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs